Wanbury Q2 profit rebounds to Rs 11.9 crore sequentially
Key highlights
- Wanbury’s Q2 FY27 revenue from operations rose 10.5% sequentially to Rs 182.9 crore.
- Wanbury’s Q2 FY27 profit after tax increased 266.4% sequentially to Rs 11.9 crore.
- Wanbury’s EBITDA margin improved to 14.3% in Q2 FY27 from 10.0% in Q1 FY27.
- Wanbury generated Rs 37.5 crore of operating cash in H1 FY27 versus Rs 5.7 crore used in H1 FY26.
powered by IRIS

Wanbury Limited reported standalone profit after tax of Rs 11.9 crore in Q2 FY27, up 266.4% from Rs 3.2 crore in Q1 FY27, as revenue from operations rose 10.5% sequentially to Rs 182.9 crore and EBITDA margin improved to 14.3% after partial customer price pass-throughs.
Know Wanbury inside out
Results, valuation, peers and who's buying, in one view.
How did Wanbury perform in Q2 FY27?
Wanbury’s standalone revenue from operations was Rs 182.9 crore in Q2 FY27, up 14.3% from Rs 160.1 crore in Q2 FY26 and 10.5% from Rs 165.6 crore in Q1 FY27. Management said the September-quarter recovery in revenue and profitability followed disruption caused by the West Asia crisis in Q1 FY27.
Earnings before interest, tax, depreciation and amortisation (EBITDA), including other income, rose 57.9% sequentially to Rs 26.2 crore from Rs 16.6 crore in Q1 FY27. EBITDA was Rs 26.0 crore in Q2 FY26, while the margin improved 431 basis points to 14.3% from 10.0% in Q1 FY27 but remained 190 basis points below 16.2% a year earlier.
Profit before tax was Rs 15.7 crore, compared with Rs 4.6 crore in Q1 FY27 and Rs 15.2 crore in Q2 FY26. Profit after tax fell 21.7% year on year from Rs 15.2 crore, while earnings per share were Rs 3.40 against Rs 4.58, because Wanbury began providing for deferred tax liabilities in FY27.
Why did Wanbury’s gross margin improve from Q1 FY27?
Wanbury’s gross margin rose to 54.2% in Q2 FY27 from 52.5% in Q1 FY27 because it passed a substantial part of higher input costs to customers during the quarter. Gross profit increased to Rs 99.1 crore from Rs 86.9 crore as revenue from operations increased by Rs 17.3 crore sequentially.
The margin recovery was not complete against the previous year: gross margin was 58.2% and gross profit was Rs 93.2 crore in Q2 FY26. Wanbury said solvents and other crude-oil-linked raw materials remained elevated following the West Asia crisis, and management expects the remaining cost increase to be passed on in the coming quarter.
Finance costs also declined to Rs 6.3 crore in Q2 FY27 from Rs 8.0 crore in Q1 FY27 and Rs 7.1 crore in Q2 FY26. Wanbury attributed the reduction to refinancing borrowings at a lower interest rate effective 1 July 2026, with management saying the related benefit should continue in coming quarters.
How did Wanbury’s H1 FY27 results compare with H1 FY26?
Wanbury’s first-half, or H1, FY27 revenue from operations rose 7.8% year on year to Rs 348.5 crore from Rs 323.2 crore in H1 FY26. However, EBITDA declined 15.7% to Rs 42.8 crore from Rs 50.8 crore, reflecting the Q1 disruption and the higher crude-linked input costs described for the half year.
Profit after tax was Rs 15.1 crore in H1 FY27, down 47.2% from Rs 28.7 crore in H1 FY26. EBITDA margin declined to 12.3% from 15.7%, while profit after tax margin fell to 4.3% from 8.9%, showing that the Q2 improvement had not offset the first-quarter effect in the half-year comparison.
Net cash generated from operating activities was Rs 37.5 crore in H1 FY27, compared with net cash used of Rs 5.7 crore in H1 FY26. This change in operating cash movement occurred alongside the reported 7.8% growth in first-half revenue, despite lower EBITDA and profit after tax.
Got a follow-up? Ask IRIS
What was the effect of Wanbury Skin Health on Q2 FY27 results?
Wanbury began presenting consolidated financial results in Q2 FY27 after incorporating Wanbury Skin Health Limited as an 82% subsidiary during the quarter. Consolidated revenue from operations was Rs 182.9 crore, EBITDA was Rs 22.9 crore and profit after tax was Rs 8.5 crore, compared with standalone EBITDA of Rs 26.2 crore and profit after tax of Rs 11.9 crore.
The subsidiary absorbed a Rs 3.4 crore loss from expenses incurred before its commercial launch in October 2026. It launched the berrysoft baby range across multiple Indian states, beginning Wanbury’s entry into paediatric dermatology with Gentle Bathing Bar, Gentle Body Wash, Foam Shampoo and Syndet Handwash.
Wanbury said Moisturising Lotion, Diaper Rash Cream and Moisturising Cream remain in the product pipeline. The subsidiary obtained goods and services tax registration in five states and carrying-and-forwarding drug licences in Mumbai, Jaipur, Patna and Ambala, and will use Wanbury’s existing paediatrician relationships for cough and cold products.
What operational developments does Wanbury expect next?
Wanbury plans to resume dispatches of Ketamine HCl anaesthetic active pharmaceutical ingredient (API) in the current quarter, with first dispatches planned in November 2026 after completion of subject matter expert regulatory audits. It is also validating Quetiapine Fumarate, Sitagliptin and Empagliflozin, with regulatory filings planned in coming quarters and sales in semi-regulated markets expected in the interim.
During July and August 2026, Wanbury received nine No DMF Deficiency letters from the United States Food and Drug Administration for its Metformin HCl Drug Master File, in connection with reviews of abbreviated new drug applications filed by customers. It also received similar letters for Paroxetine HCl and Diphenhydramine HCl, while the European Directorate for the Quality of Medicines and Healthcare granted a Certificate of Suitability for Rivaroxaban API.
Wanbury’s Tanuku site received an Australian Therapeutic Goods Administration good manufacturing practice compliance certificate on 28 October 2026 following an inspection on 8 and 9 June 2026. Valid until 9 December 2028, it covers Metformin HCl, Tramadol HCl, Sertraline HCl, Diphenhydramine HCl, Mefenamic Acid and Paroxetine HCl Hemihydrate.
Wanbury also commercialised directly compressible Metformin in Saudi Arabia, with annual revenue potential of about Rs 10 crore. In Mexico, its customer won a two-year Metformin supply tender valued at about Rs 15 crore annually, while the new Andhra Pradesh manufacturing block remains under validation for new APIs.
Conclusion
Wanbury’s Q2 FY27 figures show a clear sequential recovery in revenue, EBITDA margin and profit after tax following Q1 disruption, supported by partial price pass-through and lower finance costs. Yet the comparison with Q2 FY26 and H1 FY26 shows that elevated crude-linked material prices and deferred-tax provisions continued to weigh on year-on-year margins and profit.
The next disclosed measures are completion of the remaining customer price pass-through in the coming quarter, planned Ketamine HCl dispatches in November 2026 and progress on new API launches towards the end of FY27. Management expects these launches to affect performance in the following year and has said it expects improved second-half revenue and profitability.


